Application progress of epidermal growth factor receptor tyrosine kinase inhibitors other than lung cancer / 中国药理学通报

ABSTRACT

Epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKIs) has been mainly used for molecular targeted therapy of advanced non-small cell lung cancer. With the deeper and deeper research of EGFR-TKIs it was found that EGFR and its ligands were involved in the pathogenesis of different human cancers, such as breast cancer and pancreatic cancer. Therefore, the treatment of EGFR-TKIs is no longer limited to advanced non-small cell lung cancer, it also has a good inhibitory effect on malignant tumors such as breast cancer, pancreatic cancer, head and neck cancer, esophageal cancer and cervical cancer. Combination medications are often more effective than medication alone. The article discusses the application research of EGFR-TKIs in the treatment of cancers other than lung cancer and the potential application prospects of EGFR-TKIs combined with other drugs in the treatment of breast cancer, pancreatic cancer and other malignant tumors.